Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Tranilast with Enhanced Solubility in Gastric Fluid and Improved Oral Bioavailability

Koda, 1976, Inhibition of hypersensitivity reactions by a new drug, N(3,4-dimethoxycinnamoyl) anthranilic acid (N-5), J. Allergy Clin. Immunol., 57, 396, 10.1016/0091-6749(76)90054-3

Suzawa, 1992, Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages, Jpn. J. Pharmacol., 60, 85, 10.1254/jjp.60.85

Konneh, 1998, Tranilast Kissei Pharmaceutical. IDrugs, 1, 141

Ikeda, 1996, Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells, Biochem. Biophys. Res. Commun., 227, 322, 10.1006/bbrc.1996.1508

Uno, 2008, Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis, Hematology, 48, 109

Mori, 1991, Bleomycin-induced pulmonary fibrosis in genetically mast cell-deficient WBB6F1-W/Wv mice and mechanism of the suppressive effect of tranilast, an antiallergic drug inhibiting mediator release from mast cells, on fibrosis, Int. Arch. Allergy Appl. Immunol., 95, 195, 10.1159/000235429

Mori, 1995, Suppressive effects of tranilast on pulmonary fibrosis and activation of alveolar macrophages in mice treated with bleomycin: role of alveolar macrophages in the fibrosis, Jpn. J. Pharmacol., 67, 279, 10.1254/jjp.67.279

Izumi, 2009, Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes, Prostate, 69, 1222, 10.1002/pros.20975

Nie, 1997, Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca(2+)-permeable channel, Cell Calcium, 22, 75, 10.1016/S0143-4160(97)90107-X

Noguchi, 2003, Effects of fibroblast growth inhibitor on proliferation and metastasis of oral squamous cell carcinoma, Oral Oncol., 39, 240, 10.1016/S1368-8375(02)00092-1

Kawabata, 2010, Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability, Eur. J. Pharm. Sci., 39, 256, 10.1016/j.ejps.2009.12.009

The Society of Japanese Pharmacopoeia, 2002, Tranilast. Japanese Orange Book No, 12 (Approved drug products with therapeutic equivalence evaluations), 171

Joe, 2010, Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus, Int. J. Pharm., 395, 161, 10.1016/j.ijpharm.2010.05.023

Chiou, 1971, Pharmaceutical applications of solid dispersion systems, J. Pharm. Sci., 60, 1281, 10.1002/jps.2600600902

Vogt, 2005, Structural analysis of polymorphism and solvation in tranilast, J. Pharm. Sci., 94, 651, 10.1002/jps.20268

Vasconcelos, 2007, Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs, Drug Discov. Today, 12, 1068, 10.1016/j.drudis.2007.09.005

Friesen, 2008, Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview, Mol. Pharm., 5, 1003, 10.1021/mp8000793

Ren, 2006, Characteristics of bicalutamide solid dispersions and improvement of the dissolution, Drug Dev. Ind. Pharm., 32, 967, 10.1080/03639040600637606

Leuner, 2000, Improving drug solubility for oral delivery using solid dispersions, Eur. J. Pharm. Biopharm., 50, 47, 10.1016/S0939-6411(00)00076-X

Yada, 2003, Solid phase transition of CS-891 enantiotropes during grinding, Int. J. Pharm., 255, 69, 10.1016/S0378-5173(03)00084-X

Savolainen, 2007, Screening for differences in the amorphous state of indomethacin using multivariate visualization, Eur. J. Pharm. Sci., 30, 113, 10.1016/j.ejps.2006.10.010